Exonate are always keen to hear from highly experienced individuals in screening science, cell biology, biochemistry and pharmacology, please contact email@example.com
By exploiting the alternative splicing of vascular endothelial growth factor (VEGF) we aim to use our cutting-edge technology to introduce an eye drop to treat wet AMD and DMO. Our technology has the potential to become the patients’ treatment of choice in an area of high medical unmet need.
We have an experienced and highly- respected, international management team. Our strength is scientific expertise with cross-disciplinary experience in medicine and drug development, alongside a track record of raising capital for early stage companies. Our work is supported by highly respected Clinical and Scientific Advisory boards made up of leading international Key Opinion Leaders from the ophthalmology industry.
Learn more about Exonate and discover our latest company news, achievements and discoveries. Don’t miss a thing and get updated on our latest news.